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Reticulocyte hemoglobin content in the evaluation of iron status
of hemodialysis patients
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Reticulocyte hemoglobin content in the evaluation of iron status in
hemodialysis patients. The assessment of iron status for hemodialysis
patients has been hindered by the inaccuracy of commonly used diagnostic
tests. A novel assay, the reticulocyte hemoglobin content (CHr), has
recently been found to sensitively detect functional iron deficiency among
nonuremic patients treated with recombinant erythropoietin (rHuEPO).
The purpose of this study was to evaluate the CHr for the assessment of
iron status in hemodialysis patients. One hundred sixty-four stable hemo-
dialysis patients had a mean CHr of 27.5 2.8 pg with a normal
distribution of values. The mean CH (mature red cell hemoglobin
content) was 26.4 2.4 pg. There was a close correlation between CHr
and CH (r = 0.86, P < 0.0001). A significant subgroup of patients (12.2%)
had CHr values < CH. These patients had recent increases in rHuEPO
dose, and a lower mean transferrin saturation and hematocrit, suggesting
the recent onset of functional iron deficiency due to the increase in
rHuEPO dose. In the second phase of the study, 32 patients were
randomly selected to receive treatment with a single dose infusion of 1,000
mg of intravenous iron dextran (IVFe). Patients were classified as iron
deficient (N = 7) if they responded with a significant reticulocytosis(sustained 1 basis point increase in corrected reticulocyte index within 2
weeks). All other patients were classified as iron replete (N 25). A
CHr < 26 pg at baseline predicted iron deficiency with a sensitivity of
100%, specificity of 80%. The serum ferritin, transferrin saturation and
percentage of hypochromic red blood cells all were less accurate. The time
to correction of iron deficiency at the level of the reticulocyte was found
to be within 48 hours as measured by correction of the mean CHr to > 26
pg, and by the shift of the vast majority of the reticulocyte population to
CHr > 26 pg within this time span. We conclude that CHr < 26 pg is an
accurate measure of iron status in hemodialysis patients, that a CHr
value < CH indicates the acute onset of iron deficiency, and that a single
dose infusion of intravenous iron results in correction of iron deficiency at
the level of the reticulocyte within 48 hours.
Effective anemia management in hemodialysis patients requires
close monitoring of iron status, and effective treatment of iron
deficiency [1—31. The two tests commonly utilized to assess iron
sufficiency in these patients are the serum ferritin and transferrin
saturation. Both tests are indirect measures of iron status, and
have an unacceptable level of diagnostic accuracy in this patient
population [4]. During the intense erythropoietic stimulation of
recombinant human erythropoietin (rHuEPO) therapy, the quan-
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tity of iron immediately available for erythropoiesis often proves
insufficient despite whole body iron stores that may not be
significantly depleted. This phenomenon, termed functional iron
deficiency, may occur despite normal appearing values of serum
ferritin and transferrin saturation [5, 6]. An ideal test of iron
status in this setting would be one that directly measures iron at
the level of the erythrocyte or one of its precursors. It should be
inexpensive, and easy to use. In addition, an ideal test should
quantitate immediately available iron. Studies of red cells are
insensitive in this respect, yielding information summed over the
relatively long lifespan of these cells. Reticulocytes are the first
circulating form of red blood cells, existing in circulation for only
approximately one day [I A test evaluating reticulocytes, there-
fore, would provide a "snapshot" of iron status on the day the test
was performed.
In the past, studies of reticulocytes had been hindered by
staining procedures that altered the cellular indices. A novel
automated flow cytometry technique has recently been developed
that enables the accurate analysis of reticulocytes [8, 9]. One
parameter derived is the reticulocyte hemoglobin content (CHr).
This test satisfies the criteria that an ideal test of iron status in
hemodialysis should possess. Recent studies in nonuremic pa-
tients treated with rHuEPO demonstrated the sensitivity of this
test for detecting functional iron deficiency [10]. The purpose of
this study was to evaluate the test for the first time in hemodialysis
patients.
METHODS
Descriptive study
The purpose of the initial portion of the study was to describe
the mean and distribution of CHr values in hemodialysis patients,
and to examine patterns that might he helpful diagnostically. The
study was performed at the Winthrop-University Hospital Dialysis
Center; the protocol and informed consent form were approved
by the hospital's institutional review hoard. All patients undergo-
ing hemodialysis during one of the center's six daytime dialysis
shifts were considered eligible for study. Fifteen (8.3%) of 179
patients chose not to participate. Blood samples were drawn from
the arterial port of the remaining 164 patients at the initiation of
the dialysis treatment. The patients had a mean age of 59.6 10.8
years; the racial diversity was 68% Caucasian, 20% African-
American, 7% Hispanic, 5% other ethnicity. A total of 57% were
men, and the cause of ESRD was diabetic nephropathy in 46
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(25.7%), hypertensive nephrosclerosis in 39 (23.8%), chronic
glomerulonephritis in 22 (12.2%), polycystic kidney disease in 8
(4.8%), systemic lupus erythematosus in 6 (3.6%), interstitial
nephropathy in 4 (2.4%), obstructive nephropathy in 4 (2.4%),
renovascular disease in 3 (1.8%), and unknown 32 (22.8%).
Collected samples were immediately refrigerated, and assays
wcre performed on the same day. Reticulocytc indices, reticulo-
cyte counts, and percentage of hypochromic red blood cells were
measured using the Technicon H*3 hematology analyzer, Bayer
Diagnostic (Tarrytown, NY, USA). Mean cell hemoglobin content
(CHr) was measured as described previously [11]. Analyses were
also performed for hematocrit, serum ferritin, transferrin satura-
tion, and the percentage of hypochromic red blood cells.
Iron deficiency diagnosis study
This phase of the study was conducted to evaluate the ability of
the CHr to predict iron deficiency in hemodialysis patients, and to
compare the CHr to other commonly used diagnostic tests. Fifty
patients described in the initial cross sectional phase of study,
were selected at random. Patients were considered ineligible if
they had a serum ferritin of > 600 ng/ml, or if there was any
change in rHuEPO dose, bleeding episode, blood transfusion or
intravenous iron treatment in the previous four weeks. Thirty-two
patients met the inclusion criteria, and were enrolled in the study.
Blood was drawn at baseline, and then at the initiation of every
dialysis treatment for the subsequent two weeks. Assays per-
formed included hematocrit, reticulocyte count, reticulocyte he-
moglobin content (CHr), the percentage of hypochromic red
blood cells (cells with hemoglobin concentration < 28 gldl) and
red blood cell hemoglobin content (CH) (see above). The serum
ferritin and transferrin saturation were measured at baseline. The
corrected reticulocyte index (CR1) was calculated as the reticulo-
cyte count multiplied by the hematocrit divided by 40.
After obtaining baseline blood samples, all patients were
treated with 1,000 mg of intravenous iron dextran (INFeD; Schein
Pharmaceutical Inc., Florham Park, NJ, USA) infused over two
hours as a single-dose infusion. Patients were classified as iron
deficient or iron replete based on their erythropoietic response to
the iron treatment. Any patient with a sustained increase in the
corrected reticulocyte index of 1 basis point (e.g. from 1.7% to
2.7%) within two weeks was classified as iron deficient, all others
as iron replete.
Statistical analysis
Analyses included frequency distribution, linear regression,
Student's unpaired t-tests and the chi square statistic. All results
are presented as the mean SD. A P value of < 0.05 was
considered to be statistically significant.
RESULTS
Patient demographics are displayed in Table 1. Among the 164
patients studied, the mean reticulocyte hemoglobin content (CHr)
was 27.5 2.8 pg, and the values were distributed normally (Fig.
1). Twenty-eight percent of patients had a CHr value less than 26
pg. The mean mature red blood cell hemoglobin content (CH)
was 26.4 2.4 pg, significantly less than the mean CHr (P <
0.000 1). There was, however, a close correlation between CH and
CHr (Fig. 2, r 0.86, r2 = 0.74, P < 0.0001).
The normal relationship of CHr being greater than CH was
inverted (CHr < CH) in 20 (12.2%) patients. Characteristics of
Mean age years
Ethnicity
Caucasian
African-American
Hispanic
Other
Cause of ESRD
Diabetic nephropathy
Hypertension
Chronic glomerulonephritis
Polycystic kidney disease
Systemic lupus
Interstitial nephritis
Obstruction
Renovascular
Unknown
Mean hematocrit %
Mean CHrpg
Mean CHpg
Mean serum ferritin ng/ml
these 20 patients are presented in Table 2. Compared to patients
with CHr > CH, patients with the inverted ratio had lower mean
CHr values in the iron deficient range, 25.1 2.1 versus 27.8
2.7, respectively, P < 0.0001. The mean CH values were not
significantly different between the two groups. The patients with
inverted values, therefore, show evidence that may be consistent
with the recent development of iron deficiency. In addition,
patients with the inverted ratio had lower mean hematocrit (P =
0.02), and transferrin saturation (P = 0.03), with no significant
difference in serum ferritin. An analysis of recent medication
changes revealed that 15 of these 20 patients (75%) had at least
one increase in rHuEPO dose in the previous month. In contrast,
among the 144 patients with the normal relationship of CH 
CHr, only 33 (23%) had an increase in the rHuEPO dose in the
previous month (P < 0.0001).
In the iron deficiency diagnosis study, 21.8% of patients were
determined to be iron deficient (as defined earlier), 78.2% were
iron replete. The change in mean corrected reticulocyte index
(CR1) in the two groups is displayed in Figure 3. Among patients
defined as iron deficient, there was a significant increase in CR1
within four days of the iron therapy. The mean CHr among iron
deficient patients was 23.7 2.0 compared to 27.9 2.1 among
iron replete patients. A CHr value of <26 pg correctly identified
all 7 iron deficient patients (sensitivity 100%). Twenty of 25 iron
replete patients had CHr  26 pg (specificity 80%; Table 3). Of
the 5 patients who were iron replete but with CHr < 26 (false
positives), subsequent protein electrophoresis revealed 2 of the 5
to be thalassemia heterozygotes. If the patients with thalassemia
were excluded from analysis, the specificity of a CHr < 26 pg
increased to 86.9%. A baseline serum ferritin of < 100 ng/ml had
a sensitivity of 71.4% and a specificity of 60% for the diagnosis of
iron deficiency, a transferrin saturation of <20% had a sensitivity
of 57.1% and a specificity of 80%. The percentage of hypochromic
red blood cells (MCHC < 28 g/dl) has been advocated as an
accurate test for iron deficiency, when more than 10% of cells are
hypochromic. In this study this criterion successfully identified 3
of 7 iron deficient patients (sensitivity 42.8%) with a specificity of
80% (Table 3).
The time course of response to total dose iron therapy was
Table 1. Patient characteristics
59.6 10.8
68%
20%
7%
5%
25.7%
23.8%
12.2%
4.8%
3.6%
2.4%
2.4%
1.8%
22.8%
32.7 0.3
27.5 2.8
26.4 2.4
231.6 89.5
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Fig. 1. Distribution of reticulocyte hemoglobin content (CHr) values in 164 hemodialysis patients tested.
40 Table 2. Comparison of patients with a normal relationship of
CH < CHr to patients with inverted ratios (CHr < CH)
Parameter
CHr<CH
(N = 20)
CHr>CH
(N = 144) P value
CH pg 26.6 2.4 26.2 2.4 NS
CHr pg 25.1 2.1 27.8 2.7 <0.0001
Hematocrit % 31.2 3.8 33.0 3.3 0.02
RHuEPO dose u/tx 6820 3378 6188 4970 NS
Increase in rHuEPO 15/20 33/144 <0.0001
dose in past month
Serum ferritin ng/ml 230.2 260.3 231.8 259.1 NS
Transferrin saturation % 14.9 7.4 20.9 12.2 0.03
15 15 17 19 21 23 25 27 29 31 33 35
CH
Fig. 2. Linear regression of reticulocyte (CHr) and mature red blood cell
(CH) hemoglobin content in hemodialysis patients (r = 0.86,P < 0.0001).
assessed by studying changes in reticulocyte hemoglobin content.
Among patients defined as iron deficient, the mean CHr increased
rapidly after the administration of intravenous iron. By day 2 post
treatment the mean CHr rose significantly compared to baseline,
and remained elevated during the 11 day followup period. In
contrast, the mean CH did not significantly change after treatment
(Fig. 4). Among iron replete patients, neither the CHr nor the CH
changed significantly after iron therapy (Fig. 5). Figure 6 depicts
the distribution of hemoglobin concentrations over a population
of reticulocytes and red blood cells from one of the patients
defined as iron deficient. Frame 6a demonstrates an expected
overlap between the distributions prior to iron therapy. Frame 6b
demonstrates that by two days post iron treatment the reticulocyte
hemoglobin content distribution is shifted significantly higher into
the normal range, with no change in the red cell population.
DISCUSSION
Recently, the introduction of automated flow cytometric meth-
ods has led to the ability to perform accurate quantitative and
qualitative analyses of reticulocytes [8, 9]. Reticulocytes are the
first red blood cells to enter the circulation, where they rapidly
lose their mitochondria and ribosomes, becoming mature red cells
over a 24 hour period [7]. Several indicies of reticulocyte size and
composition can he measured with the new technology such as the
mean cell volume (MCVr), mean cell hemoglobin concentration
(MCHCr) and the reticulocyte hemoglobin content (CHr). We
chose to study the CHr because it is a more stable assay than the
others; if testing is delayed the water content of reticulocytes may
change, affecting the reticulocyte volume and hemoglobin concen-
tration, but not the hemoglobin content.
The CHr has attributes that may make it an ideal test of iron
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Table 3. Sensitivity and specificity of parameters to diagnose iron
deficiency
Parameter Sensitivity Specificity
CHr < 26 pg 100% 80%
Serum ferritin 71.4% 60%
< 100 ng/ml
Transferrin 57.1% 80%
saturation < 20%
Percent hypochromic 42.8% 80%
RBCs> 10%
Abbreviations are: CHr, reticulocyte hemoglobin content; RBC, red
blood cells.
status for hemodialysis patients. It is a direct measure of iron
availability, it provides a snapshot of iron status on the day the test
is performed, and it may be run as a by-product of a routine
complete blood count. Brugnara et al studied nonuremic volun-
teers during the initiation of rHuEPO therapy, and found that the
CHr rapidly detected the development of iron deficient erythro-
poiesis [10]. The purpose of our study was to (1) define the mean
and distribution of values for CHr among hemodialysis patients,
and (2) evaluate the CHr for the diagnosis of iron deficiency in
this population.
Initial studies by d'Onofrio et a!, in nonuremic populations,
demonstrated a mean CHr of 28.6 1.6 pg among normal
subjects [11]. We have found the mean CHr among hemodialysis
patients to be slightly lower (27.5 2.8 pg) than that in nonuremic
normal populations. This probably reflects the high prevalence of
iron deficiency in patients treated with hemodialysis [12—14]. In
fact, we found 28% of patients studied to have a CHr value in the
iron deficient range. As reported previously in nonuremic popu-
lations [11], we found the mean CHr to be slightly higher than the
mean mature red blood cell hemoglobin content (CH). In addi-
tion, we found the mean CHr was closely correlated, as would be
expected, with the mean CH. The mature pooi of red cells should
reflect the indices of reticulocytes unless there has been a recent
change in iron status. Surprisingly, a significant number of our
patients (12.2%) had inverted values, with CHr being less than the
CH. This subset of patients had the interesting characteristics of
recent increases in their rHuEPO dose, lower than expected
transferrin saturation despite normal serum ferritins, and lower
hematocrits compared to patients with the normal relationship of
CH less than CHr. The mean CHr was < 26 pg in patients with
inverted indices despite a mean CH in the normal range. Taken
together, these findings suggest that these patients had recently
developed functional iron deficiency, probably as a result of their
recent increase in rHuEPO dose. Increases in rHuEPO doses
frequently unmask iron deficiency, as the increased eiythropoietic
demand for iron outstrips the available supply. The response to
rHuEPO in this setting may be blunted, leading to a suboptimal
erythropoietic response. The development of an inverted CHr:CH
ratio (CHr < CH) after an increase in rHuEPO dose may be a
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Fig. 3. Change in corrected reticulocyte index (CR1) after treatment with
intravenous iron dextran in iron deficient compared to iron replete
hemodialysis patients. By day 4 after iron treatment the CR1 was
significantly increased among iron deficient patients ()compared to
iron replete patients (r:i) (P < 0.05).
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Fig. 4. Among iron deficient hemodialysis patients only, the change in
reticulocyte (CHr, ) and mature red blood cell hemoglobin content(CH, .-i) after treatment with intravenous iron dextran. CHr values
increased significantly within 48 hours after the iron treatment (P < 0.05).
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Fig. 5. Among iron replete hemodialysis patients only, there was no
significant change in reticulocyte (CHr, ) or mature red blood cell
hemoglobin content (CH, -i) after treatment with intravenous iron
dextran.
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Fig. 6. Histogram of cellular hemoglobin content of reticulocytes and
mature red blood cells at baseline (frame a), and two days post-
intravenous iron treatment (frame b). By day 2, the vast majority of
reticulocytes had shifted into the normal range, while the histogram for
red blood cells was unchanged. Symbols are: (U) rcticulocytes; (:)
erythrocytes.
helpful sign that iron deficient erythropoiesis has recently devel-
oped.
Assessment of iron status during stable rHuEPO therapy must
be carried out on a repeated periodic basis to ensure continued
optimal responsiveness [15]. We have found the CHr to be highly
accurate for the diagnosis of iron deficiency in hemodialysis
patients, with a value of less than 26 pg indicating the presence of
iron deficiency. The sensitivity of 100% and the specificity of 80%
were considerably higher than we found for the serum ferritin and
transferrin saturation. In a previous study we found the serum
ferritin to have no level that was accurate for the diagnosis of iron
deficiency [4]. In that same study we found the transferrin
saturation at a level of 21% to have a sensitivity of 81%, but with
a specificity of only 63%. These results are similar to those found
recently by Kalantar-Zadeh et a!, who found no useful level of the
serum ferritin, and a sensitivity and specificity of 88% and 63% for
the transferrin saturation [16].
The inaccuracy of the serum ferritin and transferrin saturation
are due primarily to the indirect method by which they assess iron
status. Ferritin is a storage complex, a small amount (on the order
of 0.05%) of which escapes into the circulation, devoid of iron.
The concentration of circulating ferritin correlates fairly well with
whole body iron storage in nonuremic subjects [17]. The serum
ferritin level, however, is frequently increased independent of iron
status by factors such as inflammation, infection, malignancy, liver
disease and alcohol use. Its behavior as an acute phase reactant
limits its diagnostic accuracy greatly [18]. The transferrin satura-
tion is calculated as serum iron divided by total iron binding
capacity (TIBC). Both elements of the calculation are potentially
problematic. The serum iron has a marked diurnal variation [19,
20], and significant variability in its measurement [21]. The TIBC
may be decreased independent of iron status in end-stage renal
disease due to malnutrition [22], and increased, like, the serum
ferritin, because it may act as an acute phase reactant. Nonethe-
less, we and others have found the transferrin saturation to be
reasonably sensitive, but not specific for the diagnosis of iron
deficiency in hemodialysis patients [4, 16].
The CHr is a direct measure in that it evaluates iron status at
the level of the erythrocyte or its precursors. The reticulocyte is an
especially helpful form of the erythrocyte to study, since it is the
first circulating erythrocyte, and because it lasts in circulation for
such a short period of time [7]. Information on iron status
obtained via reticulocytes, therefore, provide a snapshot of iron
availability at the time the test is performed. Since the CHr is
measured by a hematology analyzer, it could be tested evety few
weeks as part of a routine complete blood count. Therefore, iron
deficiency could be detected early, before it can have an adverse
effect on erythropoiesis. Currently, the only commercially avail-
able hematology autoanalyzer which performs the CHr measure-
50 ment is the Technicon H*3 manufactured by Bayer Diagnostics
Inc. (Tariytown, NY, USA). It has been estimated that the
incremental direct cost of performing a CHr at the time a
complete blood count is performed with the Technicon H*3 is
$3.34 to $3.49US [23].
A test for iron deficiency among hemodialysis patients that has
gained popularity in Europe is the percentage of hypochromic red
blood cells. When greater than 10% of erythrocytes have a
hemoglobin concentration of < 28 g/dl, iron deficiency has been
considered to be present [24, 25]. This test is a direct marker of
iron status in that it examines the eiythrocyte. However, because
of the relatively long circulating lifespan of mature erythrocytes, it
integrates information regarding iron status over too great a
period of time. It, therefore, would not be expected to sensitively
detect the acute onset of iron deficiency. This is consistent with
our findings. The test was quite specific, but lacked sensitivity.
Only a test that evaluates reticulocytes can be highly sensitive for
the diagnosis of iron deficiency. We believe the CHr to be a
superior test from a conceptual standpoint, and our initial data
seem to confirm this viewpoint.
We found that iron deficiency was rapidly corrected after
therapy with the single dose infusion of iron dextran. By day 2
after treatment, the CHr had already increased significantly into
the normal range. This may be the first demonstration of the
rapidity with which iron deficiency can be corrected at the level of
the reticulocyte. It is unclear whether the correction in CUr may
have occurred even earlier than day 2, because this was the first
data set obtained after treatment. The histogram displayed in
Figure 6 demonstrates the remarkable and rapid shift to the
production of iron replete reticulocytes. Interestingly, the mean
reticulocyte count increased significantly by day 4 after treatment,
following the improvement in CHr.
In conclusion, we believe the CHr may he an ideal test to assess
iron status for hemodialysis patients. We have found the CHr, at
a value of < 26 pg to be an accurate predictor of iron deficiency.
In addition, the finding of an inversion in the CHr:CH ratio (CHr
value less than the CH) appears to he an early indicator of the
acute development of functional iron deficiency. Finally, we have
222 Fishbane et al: Iron in hemodialysis patients
demonstrated a shift to the production of iron replete reticulo-
cytes within two days of treatment with intravenous iron in iron
deficient hemodialysis patients. Future studies will be needed to
fully evaluate the efficacy and cost effectiveness of using the CHr
to guide iron management for hemodialysis patients.
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